# A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05654454/  
OnCo record `nct05654454` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Mabscale, LLC, now recruiting.

## Summary

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05654454 by Mabscale, LLC, with 620 participants planned, started 2023-05-31 and due to reach its primary completion in 2026-12. Interventions recorded: Bevacizumab, Paclitaxel, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05654454
- Phase: 3
- Setting: Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer
- Sponsor: Mabscale, LLC
- Enrolled: 620

## Sources

- ClinicalTrials.gov NCT05654454: https://clinicaltrials.gov/study/NCT05654454

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct05654454.json